Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $50.00 price target on the stock. A number of other brokerages also recently issued reports on CRNX. Robert W. Baird upped their price target […]
More Stories
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...
Climate-ready workplaces in 2026: managing heat, flooding, ice and severe weather
Irish and British workplaces are facing severe weather with increasing frequencies, from heatwares and flash flooding to ice underfoot. Preparing...
7 Best Bespoke Smoke Vents for Large and Complex Roof Openings (2026)
Picture a main contractor in Leeds coordinating a logistics warehouse where the structural grid leaves a 2,800 mm clear zone...